

**DECLARATION FORM ON NOTHING TO DECLARE OR  
NOTHING NEW TO DECLARE**

Measure	Nothing to declare	Nothing new to declare
A, part 1		
A, part 2 (i)		
A, part 2 (ii)		
A, part 2 (iii)		
B (i)		
B (ii)	<b>X</b>	
C		
D		
E		
F		<b>X</b>
G		

Date: 15 April 2011

State Party to the Convention: GERMANY

Exchange of data on research centres and laboratories

**1. Name(s) of facility:**

Bernhard-Nocht-Institut für Tropenmedizin

**2. Responsible public or private organization or company:**

Free and Hanseatic City of Hamburg

**3. Location and postal address:**

Bernhard-Nocht-Straße 74  
D-20359 Hamburg

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence:**

- Free and Hanseatic City of Hamburg
- Volkswagen-Foundation
- European Commission

**5. Number of maximum containment units within the research centre and/or laboratory, with the indication of their respective size (m<sup>2</sup>):**

one maximum containment unit, approx. 70 m<sup>2</sup>

**6. If no maximum containment unit, indicate highest level of protection:**

n.a.

**7. Scope and general description of activities, including type(s) of micro organisms and/or toxins as appropriate:**

Diagnosis of and research on viruses causing hemorrhagic fevers (Lassa, Ebola, Marburg, Hanta)  
Development of methods for the detection of Dengue and Arena viruses, Monkey pox, Crimean-Congo fever

Exchange of data on research centres and laboratories

**1. Name(s) of facility:**

Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health

**2. Responsible public or private organization or company:**

Federal Ministry of Food, Agriculture and Consumer Protection

**3. Location and postal address:**

Südufer 10  
D-17493 Greifswald - Insel Riems

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence:**

Federal Ministry of Food, Agriculture and Consumer Protection

**5. Number of maximum containment units within the research centre and/or laboratory, with the indication of their respective size (m<sup>2</sup>):**

three maximum containment units, approx. 190 m<sup>2</sup>,  
(FMD laboratory with effluent treatment, negative pressure and HEPA filters to protect the environment according to FAO standards, no equipment for the protection of staff, therefore unsuitable for work with human pathogens)

**6. If no maximum containment unit, indicate highest level of protection:**

n.a.

**7. Scope and general description of activities, including type(s) of micro organisms and/or toxins as appropriate:**

Diagnosis of and research on animal diseases  
Veterinary medicine: mechanisms of pathogenesis, vaccines, diagnosis of Foot and mouth disease, Bovine spongiform encephalopathy, African swine fever, Classical swine fever and other animal diseases caused by viruses

Exchange of data on research centres and laboratories

**1. Name(s) of facility:**

Institut für Virologie der Philipps Universität Marburg

**2. Responsible public or private organization or company:**

Philipps-University Marburg

**3. Location and postal address:**

Hans-Meerwein-Straße 3  
D-35043 Marburg

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence:**

State of Hessen, German Research Foundation (Deutsche Forschungsgemeinschaft), Federal Ministry of Education and Research, European Union, Federal Ministry of Defence

**5. Number of maximum containment units within the research centre and/or laboratory, with the indication of their respective size (m<sup>2</sup>):**

two maximum containment units, 110 m<sup>2</sup> each

**6. If no maximum containment unit, indicate highest level of protection:**

n.a.

**7. Scope and general description of activities, including type(s) of micro organisms and/or toxins as appropriate:**

Basic research on Marburg virus, Ebola virus, Lassa virus, Nipah Virus, SARS-Corona Virus, Junin Virus and Crim-Congo Hemorrhagic Fever Virus.  
Diagnostic services in surveillance of Class 4 - viruses and smallpox virus.

**National Biological Defence Research  
and Development Program Declaration**

1) Is there a national program to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere?

Activities of such program would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

**YES**

If the answer is YES, complete Form A, part 2 (ii) which will provide a description of the program.

## National Biological Defence Research and Development Program

### II: Description

#### **1. State the objectives and funding of the program and summarize the principal research and development activities conducted in the program.**

Federal Ministry of Defence:

The RD activities of the national program include: prophylaxis, diagnostic techniques, sampling and detection techniques, toxinology, decontamination and physical protection. Summaries and objectives of all research and development projects in the field of Medical NBC Defence are published on the Internet under <http://www.sanitaetsdienst-bundeswehr.de>.

Federal Ministry of Interior:

The overall objective of the Civil Protection Research projects supported and funded by the Federal Office of Civil Protection and Disaster Assistance is to improve preparedness and response to biological threats in order to enhance protection of the first responders and the population.

In 2010 the following research projects were funded by the Federal Office of Civil Protection and Disaster Assistance (Bundesamt für Bevölkerungsschutz und Katastrophenhilfe):

- Research project (FV337) is conducted with the focus on efficacy testing of disinfectants on surfaces of personal protection equipment. In 2010 the efficacy of disinfectants against Bacillus anthracis spores and Rizin was tested. All investigations are accomplished at the Robert Koch Institute (Berlin). The objective of the project is to develop procedures in order to minimize risks of first responders in case of a biological incident. Funding in 2010 about 96 000 Euro.
- In 2010 the evaluation of real time PCR Assays by a round robin test was finished (FV359). The project was conducted by the Institute of Virology, University of Bonn Medical Centre (Bonn). The project used PCR assays which were developed in a previous research project conducted by the Bernhard Nocht Institut (see 2007 report). The objective was to improve detection and diagnostic capabilities in case of a biological threat. Funding in 2010 was about 29 205 Euro.

#### **2. State the total funding for the program and its source.**

Federal Ministry of Defence:

The total funding in 2010 was approx. 9,52 million Euro  
(whereof funding for Bundeswehr institutions was approx. 8,05 million Euro).

Federal Ministry of Interior:

The total funding in 2010 was approx. 125.205,00 Euro.

The projects are funded by the Federal Office for Civil Protection and Disaster Assistance.

**3. Are aspects of this program conducted under contract with industry, academic institutions, or in other non-defence facilities?**

Yes

**4. What proportion of the total funds for the program is expended in these contracted or other facilities?**

Federal Ministry of Defence:

approx. 15 percent (approx. 1,47 Mio Euro)

Federal Ministry of Interior:

100 percent

**5. Summarize the objectives and research areas of the program performed by contractors and in other facilities with the funds identified under para 4.**

Federal Ministry of Defence:

The objective of the contracted activities is to provide pertinent expertise and hardware to the Federal Ministry of Defence for the improvement of the B-defence capabilities. The research areas are the same as mentioned above under # 1.

Federal Ministry of Interior:


The objective of the contracted activities is to improve preparedness and response to biological threats in order to enhance protection of the first responders and the population. Research objectives of the projects are described under # 1.

**6. Provide a diagram of the organisational structure of the program and the reporting relationships (include individual facilities participating in the program).**

Federal Ministry of Interior:

The Federal Office for Civil Protection and Disaster Assistance contracts facilities like the Robert Koch Institute and the Institute of Virology and the University of Bonn Medical Centre in accordance with their expertise for the performance of Civil Protection Research projects. The contracted research facilities report to the Federal Office for Civil Protection and Disaster Control. The Office reports to the Federal Ministry of Interior.

Federal Ministry of Defence:



\* Surgeon General coordinates all biodefence R + D activities of the Bundeswehr

**7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development program, within the territory of the reporting State, or under its jurisdiction or control anywhere.**

Federal Ministry of Defence:

4 Forms A, part 2 (iii) are attached

Federal Ministry of Interior:

No Form A, part 2 (iii); the research projects under contract do not bind a substantial proportion of the resources of both the contracted facilities.



**National Biological Defence Research  
and Development Program**

**1. What is the name of the facility?**

ABC- und Selbstschutzschule der Bundeswehr  
(NBC-Defence and Self-protection School of the Bundeswehr)

**2. Where is it located?**

D-87527 Sonthofen/Allgäu, Mühlenweg 2  
(47°31 north, 10°17 east)

**3. Floor area of laboratory areas by containment level:**

BL 2	270 m <sup>2</sup>
BL 3	--
BL 4	--
Total Laboratory Floor Area	270 m <sup>2</sup>

**4. The organisational structure of the facility:**

The workload of the Biology Section of the facility is approx. 95 percent in B-defence and 5 percent in environmental protection. The following personnel figures cover the total strength for both working areas because of the engagement of some of the personnel in both areas.

I) <b>Total number of personnel:</b>	4
II) <b>Division of personnel:</b>	
Military	-
Civilian	4
III) <b>Division of personnel by category:</b>	
Scientists	1
Engineers	-
Technicians	2
Admin. and support staff	1

- IV) **Represented scientific disciplines:**  
Parasitology, toxicology, microbiology, veterinary medicine
- V) **Contractor staff:** 0
- VI) **Source of funding:** Federal Ministry of Defence
- VII) **Funding levels for the following program areas:**  
The funding for the 95 percent share for personnel, consumable items and equipment in 2010 was approx. 0,2 million Euro
- |                        |      |
|------------------------|------|
| Development            | 30 % |
| Test and Evaluation    | 20 % |
| Education and Training | 50 % |
- VIII) **Publication policy:**  
Results will be published primarily in reports to the Federal Office of Defense Technology and Procurement and to the Federal Ministry of Defence and will be presented in scientific meetings.
- IX) **Lists of public available papers and reports resulting from the work during the previous 12 month:**  
none

**5. Brief description of the biological defence work carried out at the facility, including types of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols:**

- a. Conceptual development of biological defence in the Bundeswehr
- b. Initiation of and participation in the development of biological defence material and equipment; drafting of operational requirements
- c. Review and establishment of detection methods for pathogens and toxins suitable for military use
- d. Development of identification methods for the detection of low molecular toxins
- e. Training of NBC defence personnel (theory and practice) including familiarisation with the handling of vectors, microorganisms and toxins
- f. Training support for non-military government authorities
- g. Training support for military personnel of other states
- h. Initiation and expert monitoring of studies in the field of biological defence
- i. Drafting of joint publications for biological defence

The current program covers R I and R II organisms, inactivated material of pathogens R III and R IV, insects and ticks as well as high and low-molecular toxins; no work has been done with active viruses.

No outdoor studies of biological aerosols.

**National Biological Defence Research  
and Development Program**

**1. What is the name of the facility?**

Institut für Mikrobiologie der Bundeswehr (Bundeswehr Institute of Microbiology)

**2. Where is it located?**

D-80937 München, Neuherbergstraße 11  
(48°12' north, 11°34' east)

**3. Floor area of laboratory areas by containment level:**

BL 2	1258 m <sup>2</sup>
BL 3	67 m <sup>2</sup>
BL 4	-- m <sup>2</sup>
Total Laboratory Floor Area	1325 m <sup>2</sup>

**4. The organisational structure of the facility:**

I) **Total number of personnel:** 65

II) **Division of personnel:**  
Military 41  
Civilian 24

III) **Division of personnel by category:**  
Scientists 21  
Technicians 38  
Admin. and support staff 6

IV) **Represented scientific disciplines:**

Medicine, veterinary medicine, microbiology, virology, bacteriology, immunology, molecular biology, epidemiology, laboratory medicine

- V) **Contractor staff:** 4
- VI) **Source of funding:** Federal Ministry of Defence

VII) **Funding levels for the following program areas:**

The funding for personnel, consumable items and equipment in 2010 was approx. 5 million Euro.

Research	40 %
Development	25 %
Test and Evaluation	25 %
Education and Training	10 %

VIII) **Publication policy:**

Results are published in scientific journals as well as in reports to the Federal Ministry of Defence and will be presented in national and international scientific meetings.

IX) **Lists of public available papers and reports resulting from the work during the previous 12 month:**

see Annex 1

**5. Brief description of the biological defence work carried out at the facility, including types of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols:**

- a. Research, development and evaluation of approaches for the rapid detection, identification and differentiation and typing of *Orthopoxviruses*, *Alpha-*, *Flavi-*, *Bunya-* and *Filoviruses* as well as *Coxiella*, *Burkholderia*, *Yersinia*, *Brucella*, *Bacillus* and *Francisella spp.* using polyclonal and monoclonal antibodies, biochemical methods and real-time-PCR
- b. Establishment of sequence data banks and tools for forensic typing
- c. Evaluation and production of test kits for the immunodiagnosis of relevant infections
- d. Studies of the epidemiology, immunopathogenesis and immune response against *Francisella tularensis*, *Bacillus spp.*, *Burkholderia spp.*, *Brucella spp.* and *Yersinia spp.*

The current program covers R I, R II and R III organisms.

No outdoor studies of biological aerosols have been conducted.

## National Biological Defence Research and Development Program

### 1. What is the name of the facility?

Wehrwissenschaftliches Institut für Schutztechnologien – ABC-Schutz  
(Federal Armed Forces Scientific Institute for Protection Technologies  
and NBC-Protection)

### 2. Where is it located?

D-29633 Munster/Oertze, Humboldtstrasse, Germany  
(53°00 North, 10°08 East)

### 3. Floor area of laboratory areas by containment level:

BL 2	520 m <sup>2</sup>
BL 3	360 m <sup>2</sup>
BL 4	---- m <sup>2</sup>
Total Laboratory Floor Area	880 m <sup>2</sup>

### 4. The organisational structure of the facility:

The workload of the Biological Department of the facility is approx. 90 percent in B-defence and approx. 10 percent in bio-analytics. The following personnel figures cover the total strength for both working areas because of the engagement of some of the personnel in both areas.

I)	<b>Total Number of personnel:</b>	34
II)	<b>Division of personnel Civilian</b>	34
III)	<b>Division of personnel by category</b>	
	Scientists	7
	Engineers	5
	Technicians	17
	Admin and support staff	5

- IV) **Represented scientific disciplines:**  
 Biology, biochemistry, immunology, molecular biology, bacteriology, mycology, virology, toxicology, toxinology, biotechnology, pathology, environmental toxicology, ecology, veterinary medicine, biotechnology, aerosol biology
- V) **Contractor staff:** 2
- VI) **Source of funding:**  
 Federal Ministry of Defence
- VII) **Funding levels for the following program areas:**  
 The funding for the 90 percent share for personnel, consumable items and equipment in 2010 was approx. 2,1 million Euro.
- |                     |      |
|---------------------|------|
| Research            | 40 % |
| Development         | 30 % |
| Test and Evaluation | 30 % |
- VIII) **Publication policy**  
 Results will be published primarily in reports to the Federal Office of Defense Technology and Procurement and to the Federal Ministry of Defence.
- IX) **Lists of publicly available papers and reports resulting from the work during the previous 12 months (not included poster and other presentations):**
- BACHMANN, U., W. BIEDERBICK, N. DERAQSHANI, M. DROBIG, J.-T. EISHEH, M. KÖNIG, R. MAIER, J. MENTFEWITZ, B. NIEDERWÖHRMEIER, H. PRAST, D. SEBASTIAN, G. UELPENICH, M. VIDMAYER, S. WILBERT und M. WOLF (2010): Empfehlungen für die Probennahme zur Gefahrenabwehr im Bevölkerungsschutz - zur Analytik von chemischen, biologischen und radioaktiven Kontaminationen - Hrsg.: Bundesamt für Bevölkerungsschutz und Katastrophenhilfe, Bonn, ISBN-13: 978-3-939347-15-6
- TALBOT, S.R., H. RUSSMANN, S. KÖHNE, B. NIEDERWÖHRMEIER, G. GROTE and T. SCHEPER (2010): Effects of inactivation on the analysis of *Bacillus atrophaeus* endospores using real-time PCR and MALDI-TOF-MS. Engineering in Life Sciences, Volume 10, Issue 2, p. 109-120, April 2010
- WELLERT, S., H.-J. ALTMANN, A. RICHARDT, A. LAPP, P. FALUS, B. FARAGO and T. HELLWEG (2010): Dynamics of the interfacial film in bicontinuous microemulsions based on a partly ionic surfactant mixture: A neutron spinecho study. European Physical Journal E 33, p. 243-250
- WELLERT, S., M. KARG, O. HOLDERER, A. RICHARDT, T. HELLWEG (2010): Temperature dependence of the surfactant film bending elasticity in a bicontinuous sugar surfactant based microemulsion: a quasielastic scattering study. Physical Chemistry Chemical Physics, 1-8, - in print -

ZOLL, G., I. MATTMANN, G. GROTE and S. KÖHNE (2010): Automated DNA extraction from environmental soil samples using the Maxwell 16 System. PROMEGA Corporation Website; 1, tpub\_027. Available from: [http://www.promeqa.com/pubs/tpub\\_027.htm](http://www.promeqa.com/pubs/tpub_027.htm)

ZOLL, G. und S. KÖHNE (2010): Automatisierte DNA-Extraktion aus Bodenproben. BIOSpektrum 05.10

**5. Brief description of the biological defence work carried out at the facility, including types of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols:**

- a. Development of early-warning systems permitting non-specific identification of toxins, microorganisms and viruses.
- b. Optimization of the properties of the available, previously generated detection molecules in their specificity, affinity and avidity for use in the immunological detection and identification systems, which inevitable must be suitable also for field-use. Using new technologies (e.g. development and identification of recombinant antibodies), the repertoire of antibodies and detection molecules for biological agents is constantly expanding.
- c. Optimization and automatization of immunological and molecular genetic identification methods
- d. Development of equipment and procedures for sampling and rapid and accurate identification of toxins and pathogenic agents in samples from air, water, soil, vegetation (sensor-equipment, collectors, detection kits, automatization)
- e. Sample preparation for identification in different matrices.
- f. Development of procedures for disinfection and decontamination
- g. B-Agents and toxin laboratory analysis of suspect samples
- h. Participation in round-robin-exercises
- i. Nanotechnology for material like clothes, paint etc.

The current program covers non-human/-animal pathogens R I and pathogenic R II and R III organisms as well as low-molecular weight toxins.

Outdoor studies were performed with commercial "Xentari" (*Bacillus thuringiensis* var. *aizawai*) as a simili for biological aerosols. For disinfection-tests *Bacillus subtilis*, *Bacillus thuringiensis* and *Bacillus atrophaeus* were used as simili. For water-purification-tests *Pseudomonas fluorescens*, *Escherichia coli* (R I) and *Micoroccus luteus* were used as simili outside the laboratory.

**National Biological Defence Research  
and Development Program**

**1. What is the name of the facility?**

Zentrales Institut des Sanitätsdienstes der Bundeswehr Kiel, Laborgruppe Spezielle Tierseuchen- und Zoonosendiagnostik (Central Institute of the Bundeswehr Medical Service Kiel, Laboratory for Infectious Animal Diseases and Zoonosis).

**2. Where is it located?**

D-24119 Kronshagen, Kopperpahler Allee 120.  
(54°20'24'' north, 10°05'37'' east)

**3. Floor area of laboratory areas by containment level:**

BL 2	274 m <sup>2</sup>
BL 3	47 m <sup>2</sup>
BL 4	--
Total Laboratory Floor Area	321 m <sup>2</sup>

**4. The organisational structure of the facility:**

The workload is 70 percent in the diagnosis of infectious animal diseases and zoonosis and 30 percent in B-defence.

I) **Total number of personnel:** 5

II) **Division of personnel:**  
Military 3  
Civilian 2

III) **Division of personnel by category:**  
Scientists 2  
Technicians 3

IV) **Represented scientific disciplines:**  
veterinary medicine, microbiology, virology, bacteriology, parasitology,  
molecular biology, immunology

V) **Contractor staff:** 0



VI) **Source of funding:** Federal Ministry of Defence

VII) **Funding levels for the following program areas:**

The funding for consumable items and equipment in 2010 was approx. 0,75 million Euro.

Development	35 %
Test and Evaluation	25 %
Diagnosis	35 %
Education and training	5 %

VIII) **Publication policy:**

Results will be published primarily in reports to the Federal Ministry of Defence and in journals for military medicine or technology

IX) **Lists of public available papers and reports resulting from the work during the previous 12 month:**

A. Binder, J. Teifke, G. Saturday, B. Hoffmann, C. Freuling, T. Müller, S. Sauer: Tollwut - Entwicklung einsatzorientierter Diagnostikverfahren (Rabies - Development of Diagnostic Tests for Deployment) Wehrmedizinische Monatsschrift 2010, 54, S. 290-292

**5. Brief description of the biological defence work carried out at the facility, including types of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols:**

- a. Development and evaluation of diagnostic systems permitting specific identification of microorganisms, viruses and toxins
- b. Development of test kits for use in a deployable containerised field laboratory
- c. Diagnosis of zoonoses i.e. Q-fever, anthrax, rabies, leishmaniasis, avian influenza and other influenza viruses
- d. Diagnosis of infectious animal diseases, especially swine fever and babesiosis
- e. Diagnosis of food and waterborne threats, i.e. *Vibrio cholerae* and Norovirus
- f. Evaluation of test kits for the detection of *Clostridium botulinum* toxins
- g. Development of test kits for the detection of ricin

The current program covers R I, R II and R III organisms.

No outdoor studies of biological aerosols.

## Publications

### Bundeswehr Institute of Microbiology

2010

#### Peer Reviewed Papers

Al Dahouk S, Scholz HC, Tomaso H, Bahn P, Göllner C, Karges W, Appel B, Hensel A, Neubauer H, Nöckler K. (2010). Differential phenotyping of *Brucella* species using a newly developed semi-automated metabolic system. *BMC Microbiology* Oct 23;10:269.

Busse HJ, Huber B, Anda P, Escudero R, Scholz HC, Seibold E, Splettstoesser WD, Kämpfer P. (2010). Objections to the transfer of *Francisella novicida* to the subspecies rank of *Francisella tularensis* - response to Johansson et al. *International Journal of Systematic and Evolutionary Microbiology* Aug;60(Pt 8):1718-20

Carhan A, Uyar Y, Ozkaya E, Ertek M, Dobler G, Dilcher M, Wanf Y, Spiegel M, Hufert F, Weidmann M. (2010). Characterization of a Sandfly fever Sicilian virus isolated during a sandfly fever epidemic in Turkey. *Journal of Clinical Virology* 48, 264-269.

Długaiczek J, Traxdorf M, Zwerina J, Schwarz S, Splettstoesser W, Geißdörfer W, Schoerner C (2010). Oropharyngeal tularemia - a differential diagnosis of tonsillopharyngitis and cervical lymphadenitis. *Wiener Klinische Wochenschrift* 122, 110-114

Dobler G (2010). Alles was Sie zur FSME wissen müssen. *MMW-Fortschr. Med.* 152, 44-47.

Dobler G (2010). Zoonotic tick-borne flaviviruses. *Veterinary Microbiology* 140, 221-228.

Dörrbecker B, Dobler G, Spiegel M, Hufert F (2010). Tick-borne encephalitis and the immune response of the mammalian host. *Travel Medicine and Infectious Diseases* 8, 213-222, 2010.

Essbauer S, Pfeffer M, Meyer H (2010). Zoonotic poxviruses: actual perspectives on well known old enemies. *Veterinary Microbiology* 140(3-4), 229-236.

Fritsch J, Splettstoesser WD (2010). Septic pneumonic tularaemia caused by *Francisella tularensis* subsp. *holarctica* biovar II. *Journal of Medical Microbiology* 59, 1123-5

Goller KV, Fyumagwa RD, Kilewo M, East M L, Speck S, Müller T, Matzke M, Wibbelt G (2010). Fatal Canine Distemper Infection in a Pack of African Wild Dogs in the Serengeti Ecosystem, Tanzania. *Veterinary Microbiology*, 146: 245-252.

Guivier E, Galan M, Salvador AR, Xuéreb A, Chaval Y, Olsson GE, Essbauer S, Henttonen H, Voutilainen L, Cosson JF, Charbonnel N (2010). TNF-alpha expression and promoter sequences reflect the balance of tolerance/resistance to Puumala hantavirus infection in European bank vole populations. *Infections, Genetics and Evolution* 10(8), 1208-1217.

- Hauri AM, Hofstetter I, Seibold E, Kaysser P, J. Eckert, H. Neubauer, and Splettstoesser WD (2010). An airborne outbreak of tularemia in Germany – Epidemiological and laboratory investigations. *Emerging Infectious Diseases* 16, 238-243
- Hemmer CJ, Littmann M, Loebermann M, Meyer H, Petschaelis A and Reisinger EC (2010). Human cowpoxvirus infection acquired from a circus elephant in Germany. *International Journal of Infectious Diseases* 14 Suppl 3:e338-40. Epub 2010 Jun 26
- Huber BE, Escudero R, Busse HJ, Seibold E, Scholz HC, Anda P, Kämpfer P, Splettstoesser WD (2010). Description of *Francisella hispaniensis* sp. nov., isolated from human blood, reclassification of *Francisella novicida* (Larson et al. 1955) Olsufiev et al. 1959 as *Francisella tularensis* subsp. *novicida* comb. nov., and emended description of the genus *Francisella*. *International Journal of Systematic and Evolutionary Microbiology* Aug;60(Pt 8):1887-96
- Huemer HP, Essbauer S, Irschick EU (2010). Tissue damage caused by animal orthopoxviruses cowpox, ectromelia, vaccinia and parapoxvirus ovis in human cornea. *Acta Ophthalmologica* 88(7):e275-276
- Jiménez de Bagüés MP, Ouahrani-Bettache S, Quintana JF, Mitjana O, Hanna N, Bessoles S, Sanchez F, Scholz HC, Lafont V, Köhler S, Occhialini A (2010). The new species *Brucella microti* replicates in macrophages and causes death in murine models of infection. *Journal of Infectious Diseases* 1;202(1):3-10.
- Kaiser R, Dobler G (2010). Japan-Enzephalitis und Zecken-Enzephalitis: Ähnlichkeiten und Unterschiede. *MMW Fortschr. Med.* 152 (15), 44-45.
- Kämpfer P, Huber B, Busse HJ, Scholz HC, Tomaso H, Hotzel H, Melzer F. (2010). *Ochrobactrum pecoris* sp. nov., isolated from farm animals. *International Journal of Systematic and Evolutionary Microbiology* Oct 15. [Epub ahead of print]
- Kämpfer P, Scholz HC, Langer S, Wernery U, Wernery R, Johnson B, Joseph M, Lidders N, Busse HJ (2010). *Camelimonas lactis* gen. nov., sp. nov., isolated from the milk of camels. *International Journal of Systematic and Evolutionary Microbiology* 60(Pt 10):2382-6.
- Kaysser P, von Bomhard W, Dobrzykowski L and Meyer H (2010). Genetic diversity of feline cowpox virus, Germany 2000–2008. *Veterinary Microbiology* 141: 282-288
- Kupca A, Essbauer S, Zöller G, de Mendonca PG, Brey R, Rinder M, Pfister K, Spiegel M, Doerrbecker B, Pfeffer M, Dobler G (2010). Isolation and molecular characterization of a tick-borne encephalitis virus strain from a new tick-borne encephalitis focus with severe cases in Bavaria, Germany. *Ticks Tick-Borne Diseases* 1, 44-51.
- Li Y, Meyer H, Zhao H and Damon IK (2010). GC content-based pan-pox universal PCR assays for poxvirus detection. *Journal of Clinical Microbiology* 48: 268-276
- Mayer-Scholl A, Draeger A, Göllner C, Scholz HC, Nöckler K (2010). Advancement of a multiplex PCR for the differentiation of all currently described *Brucella* species. *Journal of Microbiological Methods* 80(1):112-4.
- Mertens M, Essbauer SS, Rang A, Schröder J, Splettstoesser WD, Kretzschmar C, Krüger DH, Groschup MH, Mätz-Rensing K, Ulrich RG. (2010). Non-human primates in outdoor enclosures: Risk for infection with rodent-borne hantaviruses. *Veterinary Microbiology* Jul 24. [Epub ahead of print]
- Mühldorfer K, Schwarz S, Fickel J, Wibbelt G, Speck S (2010). Genetic diversity of *Pasteurella* species isolated from European vespertilionid bats. *Veterinary Microbiology*, doi:10.1016/j.vetmic.2010.10.002

- Mühldorfer K, Wibbelt G, Haensel J, Riehm J, Speck S (2010). *Yersinia* Species isolated from bats, Germany. *Emerging Infectious Diseases* 16(3): 578-580.
- Pfeffer M, Hanus I, Löscher T, Homeier T, Dobler G (2010). Chikungunya fever in two German tourists returning from the Maldives, September 2009. *Eurosurveillance* 15(13), 19531.
- Pfeffer M., Dobler G (2010). Emergence of zoonotic arboviruses by animal trade and migration. *Parasites & Vectors* 3, 35-49.
- Riehm JM, Rahalison L, Scholz HC, Thoma B, Pfeffer M, Razanakoto LM, Al Dahouk S, Neubauer H, Tomaso H (2010). Detection of *Yersinia pestis* using real-time PCR in patients with suspected bubonic plague. *Molecular Cellular Probes*. 2011 25(1):8-12. Epub 2010 Oct 8.
- Rimoin AW, Mulembakanic PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkelac TL, Blumberg S, Thomassen HR, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham PS, Formenty P, Okitolonda E, Hensley LE, Meyer H, Wright LL, and Muyembe JJ (2010). Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proceedings of the National Academy of Sciences USA* 107(37):16262-7. Epub 2010 Aug 30.
- Ruzek D, Dobler G, Donoso-Mantke O (2010). Tick-borne encephalitis: pathogenesis and clinical implications. *Travel Medicine and Infectious Diseases* 8, 223-232
- Schex S, Dobler G, Riehm J, Müller, J, Essbauer S (2010). *Rickettsia* spp. In Wild Small Mammals in Lower Bavaria, South-Eastern Germany. *Vector Borne Zoonotic Diseases* Oct 6. [Epub ahead of print].
- Schmidt-Chanasit J, Essbauer S, Petraityte R, Yoshimatsu K, Tackmann K, Conraths FJ, Sasnauskas K, Arikawa J, Thomas A, Pfeffer M, Scharninghausen JJ, Splettstoesser W, Wenk M, Heckel G, Ulrich RG (2010). Extensive host sharing of central European Tula virus. *Journal of Virology* Jan;84(1):459-74.
- Schmoldt S, Bruns CJ, Rentsch M, Siegert S, Nikolaou K, Hogardt M, Heesemann J, Tappe D (2010). Skin fistulization associated with extensive alveolar echinococcosis, *Annals of Tropical Medicine & Parasitology*, Vol. 104, No. 2, 175–180
- Seibold E, Maier T, Kostrzewa M, Zeman E, and Splettstoesser WD (2010). Identification of *Francisella tularensis* by whole-cell Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry: Fast, reliable, robust and cost-effective differentiation on species and subspecies level. *Journal of Clinical Microbiology* Feb Epub ahead of print
- Splettstoesser WD, Guglielmo-Viret V, Seibold E, Thullier P (2010). Evaluation of an immunochromatographic test (ICT) for the rapid and reliable serodiagnosis of human tularemia and the detection of *F. tularensis*-specific antibodies in serum from different mammalian species. *Journal of Clinical Microbiology* 48(5):1629-34
- Splettstoesser WD, Seibold E, Zeman E, Trebesius K, Podbielski A (2010). Rapid Differentiation of *Francisella* Species and Subspecies by Fluorescent In Situ Hybridization Targeting the 23 S rRNA. *BMC Microbiology* 10:72 Epub ahead of print
- Süss J, Kahl O, Aspöck H, Hartelt K, Vaheri A, Oehme R, Hasle G, Dautel H, Kunz C, Kupreviciene N, Randolph S, Zimmermann HP, Atkinson B, Dobler G, Kutsar K, Heinz FX, Steffen R (2010). Tick-borne encephalitis in the age of general mobility. *Wiener Medizinische Wochenschrift* 160, 94-100.
- Tomaso H, Kattar M, Eickhoff M, Wernery U, Al Dahouk S, Straube E, Neubauer H, Scholz HC (2010). Comparison of commercial DNA preparation kits for the detection of *Brucellae* in tissue using quantitative real-time PCR. *BMC Infectious Diseases* 20;10:100.

## Germany

Form B (i)

### Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

#### Human Diseases (cases)

	2006	2007	2008	2009	2010
<b>Anthrax</b>	0	0	0	1	1
<b>Botulism</b>	6	9	10	7	4
<b>Brucellosis</b>	37	21	24	19	22
<b>Cholera</b>	1	2	0	0	6
<b>Glanders</b>	0	0	0	0	0
<b>Ornithosis</b>	26	12	22	26	25
<b>Plague</b>	0	0	0	0	0
<b>Q-fever</b>	204	83	370	191	360
<b>Shigellosis</b>	817	869	574	617	731
<b>Smallpox</b>	0	0	0	0	0
<b>Tularemia</b>	1	20	15	10	31
<b>Typhus abdominalis</b>	75	59	69	65	71
<b>Typhus fever</b>	0	0	0	0	0
<b>Viral encephalitis</b>	0	0	0	0	0
<b>Viral hemorrhagic fever</b>	1*	0	3**	3**, 1***	1**
<b>Yellow fever</b>	0	0	0	0	0

\* Lassa

\*\* Dengue

\*\*\* Krim Kongo

## Germany

Form B (i)

### Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

#### Animal Diseases (outbreaks)

	2006	2007	2008	2009	2010
<b>African swine fever</b>	0	0	0	0	0
<b>Anthrax</b>	0	0	0	2	0
<b>Aujeszky's disease</b>	0	0	0	4**	3**
<b>Bovine Brucellosis</b>	0	0	0	0	0
<b>Foot and mouth disease</b>	0	0	0	0	0
<b>Classical swine fever of domestic pigs</b>	8	0	0	0	0
<b>Newcastle disease</b>	0	0	1	0	1
<b>Psittacosis</b>	83	154	134	152	76
<b>Q fever</b>	96	109	162	139	137
<b>Rabies</b>	11	6	9*	4***	4****
<b>Rinderpest</b>	0	0	0	0	0
<b>Sheep pox</b>	0	0	0	0	0
<b>Swine vesicular disease</b>	0	0	0	0	0
<b>Teschen disease</b>	0	0	0	0	0
<b>Tularemia</b>	4	6	12	14	24

\* bats in 8 districts, dog in 1 district / \*\* dogs / \*\*\* bats / \*\*\*\* bats in 3 districts, dog in 1 district

## Exchange of Information on Published Results

In **2010** scientific papers related to research and development for prophylactic and/or protective measures against microbial and biological agents and toxins sponsored by the Federal Ministry of Defence have been published inter alia in the following journals:

Acta Ophthalmologica  
Annals of Tropical Medicine & Parasitology  
BMC Infectious Diseases  
BMC Microbiology  
Emerging Infectious Diseases  
Engineering in Life Sciences  
European Physical Journal  
Eurosurveillance  
Infections, Genetics and Evolution  
International Journal of Infectious Diseases  
International Journal of Systematic and Evolutionary Microbiology  
Journal of Clinical Microbiology  
Journal of Clinical Virology  
Journal of Infectious Diseases  
Journal of Medical Microbiology  
Journal of Microbiological Methods  
Journal of Virology  
MMW – Fortschritte der Medizin  
Molecular Cellular Probes  
Parasites & Vectors  
Physical Chemistry Chemical Physics  
Proceedings of the National Academy of Sciences USA  
Ticks and Tick-Borne Diseases  
Travel Medicine and Infectious Diseases  
Vector Borne Zoonotic Diseases  
Veterinary Microbiology  
Wehrmedizinische Monatsschrift  
Wiener klinische Wochenschrift  
Wiener Medizinische Wochenschrift

## Active Promotion of Contacts

### **Planned international conferences, symposia, seminars and other similar forums for exchange**

Name of the conference	Medical Biodefence Conference 2011
Arranging organization	Bundeswehr Institute of Microbiology
Time	25 – 28 October 2011
Place	München
Main subjects	<ol style="list-style-type: none"><li>1. Bioforensics</li><li>2. Diagnostics and therapeutics</li><li>3. Epidemiology and Surveillance</li><li>4. Outbreak investigation and management of highly contagious patients</li><li>5. Objectives and results of the German biological medical defence research and development program</li></ol>
Conditions for participation	Experts named by States Parties
Point of contact for further information, registration etc.	Col Prof. Dr. Zöller Bundeswehr Institute of Microbiology D-80937 München, Neuherbergstr. 11 Phone: +49-89-3168-3981 Fax: +49-89-3168-3983 e-mail: <a href="mailto:institutfuermikrobiologie@bundeswehr.org">institutfuermikrobiologie@bundeswehr.org</a>  <a href="http://www.biodefense2011.org">www.biodefense2011.org</a>



# Germany

Form E

## Declaration of Legislation, Regulations and Other Measures

<b>RELATING TO MEASURES</b>	<b>LEGISLATION</b>	<b>REGULATIONS</b>	<b>OTHER</b>	<b>AMENDED SINCE LAST YEAR</b>
a) Development, production, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	NO	All pertinent legislation related to a), b), and c) is available with links to updated source documents on the ISU National Implementation Database website ( <a href="http://www.unog.ch">www.unog.ch</a> )
b) Exports of microorganisms* and toxins	YES	YES	NO	
c) Imports of microorganisms* and toxins	YES	YES	NO	

\* Microorganisms pathogenic to humans, animals and plants in accordance with the Convention

## Declaration of Vaccine Production Facilities

**A.1. Name of Facility:**

Novartis Vaccines and Diagnostics GmbH

**2. Location (mailing address):**

Postfach 1630  
D-35006 Marburg

**3. General description of the types of diseases covered:**

botulism (antitoxin), diphtheria, influenza, pertussis, rabies, tetanus, tick-borne encephalitis, meningococcal meningitis A, B, C, W, Y

**B.1. Name of Facility:**

GlaxoSmithKline Biologicals  
(Branch of SmithKline Beecham Pharma GmbH & Co KG)

**2. Location (mailing address):**

Zirkusstr. 40  
D-01069 Dresden

**3. General description of the types of diseases covered:**

influenza

**C.1. Name of Facility:**

IDT Biologika GmbH

**2. Location (mailing address):**

Postfach 400214  
D-06861 Dessau-Roßlau

**3. General description of the types of diseases covered:**

smallpox (vaccinia virus vaccines; Investigational Medicinal Product), HIV (Investigational Medicinal Product), malaria (Investigational Medicinal Product), Filovirus vaccines (Investigational Medicinal Product), Salmonella typhi (oral live vaccine; Investigational Medicinal Product)

**D.1. Name of Facility:**

Rhein Biotech GmbH  
Dynvax Europe

**2. Location (mailing address):**

Eichsfelder Strasse 11  
D-40595 Düsseldorf

**3. General description of the types of diseases covered:**

hepatitis B (commissioned production, no own licence for marketing)

**E.1. Name of Facility:**

Bavaria Nordic GmbH

**2. Location (mailing address):**

Robert-Rössle-Strasse 10  
D-13125 Berlin

**3. General description of the types of diseases covered:**

smallpox (vaccinia virus vaccines; Investigational Medicinal Product), infectious diseases (vaccinia virus vaccines), cancer diseases (vaccinia virus vaccines, fowlpox virus vaccines)

**F.1. Name of Facility:**

Vibalogics GmbH

**2. Location (mailing address):**

Zeppelinstraße 2  
D-27472 Cuxhaven

**3. General description of the types of diseases covered:**

tuberculosis bacterial vaccine (commissioned production for clinical trials, no own license for marketing)